Authors
Rodrigo Poves-Álvarez, Olga de la Varga-Martínez, Rosalía Navarro Pérez, Marina Varela Duran, Rafael Badenes, Eduardo Santamaría-Vázquez, Nekane Romero-García, Eduardo Tamayo, Rocío López Herrero
Published in
Anaesthesia, critical care & pain medicine. Pages 101993. Nov 15, 2026. Epub Nov 15, 2026.
Abstract
European product information does not recommend sugammadex in severe renal impairment, including dialysis, because renal elimination is markedly reduced. European data describing reversal practice in this population are limited.
To determine whether sugammadex was the predominant pharmacological reversal agent among patients in GFR categories G4-G5 or receiving dialysis.
This secondary analysis of the prospective DELPO cohort included adults who received general anaesthesia, neuromuscular blockade, and pharmacological reversal with sugammadex or neostigmine at 43 Spanish hospitals. Patients were classified as being in GFR categories G1-G3 (eGFR ≥30 mL min-¹ 1.73 m-²) or GFR categories G4-G5 or receiving dialysis (eGFR <30 mL min-¹ 1.73 m-² or dialysis). Reversal-agent use was described overall and according to renal function.
The analysis included 1331 patients, of whom 35 were in GFR categories G4-G5 or receiving dialysis, including 20 receiving dialysis. Sugammadex was used in 1,278 of 1,331 patients overall (96.0%), in 1248 of 1,296 patients in GFR categories G1-G3 (96.3%), and in 30 of 35 patients in GFR categories G4-G5 or receiving dialysis (85.7%; 95% CI, 70.6-93.7%). Among the 20 patients receiving dialysis, sugammadex was administered to 16 (80.0%; 95% CI, 58.4-91.9%).
Among patients in GFR categories G4-G5 or receiving dialysis who received pharmacological reversal, sugammadex was used in 85.7% (30/35), including 80.0% (16/20) of patients receiving dialysis, despite current European product information not recommending its use in this population.
PMID:
43035147
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0